Myriad Genetics, Inc. (LON:0K3W)

Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of GBP 450.23 million. The enterprise value is 501.28 million.

Market Cap	450.23M
Enterprise Value	501.28M

Important Dates

The last earnings date was Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	93.21M
Shares Outstanding	n/a
Shares Change (YoY)	+2.77%
Shares Change (QoQ)	+0.65%
Owned by Insiders (%)	2.64%
Owned by Institutions (%)	92.37%
Float	85.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	158.80
PS Ratio	0.73
PB Ratio	1.62
P/TBV Ratio	3.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.68
EV / Sales	0.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-40.35

Financial Position

The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.57.

Current Ratio	2.33
Quick Ratio	1.78
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	-12.71
Interest Coverage	-12.07

Financial Efficiency

Return on equity (ROE) is -72.52% and return on invested capital (ROIC) is -7.03%.

Return on Equity (ROE)	-72.52%
Return on Assets (ROA)	-5.67%
Return on Invested Capital (ROIC)	-7.03%
Return on Capital Employed (ROCE)	-14.15%
Revenue Per Employee	227,398
Profits Per Employee	-110,351
Employee Count	2,700
Asset Turnover	0.91
Inventory Turnover	8.46

Taxes

Income Tax	-18.45M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -62.01% in the last 52 weeks. The beta is 1.78, so Myriad Genetics's price volatility has been higher than the market average.

Beta (5Y)	1.78
52-Week Price Change	-62.01%
50-Day Moving Average	7.50
200-Day Moving Average	7.92
Relative Strength Index (RSI)	33.93
Average Volume (20 Days)	2,590

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.61

Income Statement

In the last 12 months, Myriad Genetics had revenue of GBP 613.97 million and -297.95 million in losses. Loss per share was -3.24.

Revenue	613.97M
Gross Profit	432.01M
Operating Income	-61.08M
Pretax Income	-316.40M
Net Income	-297.95M
EBITDA	-19.49M
EBIT	-61.08M
Loss Per Share	-3.24

Balance Sheet

The company has 108.17 million in cash and 157.94 million in debt, giving a net cash position of -49.77 million.

Cash & Cash Equivalents	108.17M
Total Debt	157.94M
Net Cash	-49.77M
Net Cash Per Share	n/a
Equity (Book Value)	277.34M
Book Value Per Share	2.98
Working Capital	146.41M

Cash Flow

In the last 12 months, operating cash flow was -1.64 million and capital expenditures -10.79 million, giving a free cash flow of -12.42 million.

Operating Cash Flow	-1.64M
Capital Expenditures	-10.79M
Free Cash Flow	-12.42M
FCF Per Share	n/a

Margins

Gross margin is 70.36%, with operating and profit margins of -9.95% and -48.53%.

Gross Margin	70.36%
Operating Margin	-9.95%
Pretax Margin	-51.53%
Profit Margin	-48.53%
EBITDA Margin	-3.17%
EBIT Margin	-9.95%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.77%
Shareholder Yield	-2.77%
Earnings Yield	-66.18%
FCF Yield	-2.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Myriad Genetics has an Altman Z-Score of 0.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.58
Piotroski F-Score	4